Court Could Pause Medicare Drug Price Negotiation Process Following First Hearing In IRA Litigation
Executive Summary
Ahead of Friday’s hearing on US Chamber of Commerce's suit against HHS, attorneys discuss potential remedies and carveouts to Inflation Reduction Act's drug price negotiation provisions, harms to industry that may support a preliminary injunction, and what would prompt Supreme Court review.
You may also be interested in...
Big Rebates Already A Big Factor For Drugs On Medicare Negotiation List
Long-awaited list has a couple of surprises that are expected to face biosimilar competition either before negotiated prices are implemented in 2026 or during that year.
Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program
Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.
What To Expect As IRA Legal Challenges Mount
Second lawsuit filed against the IRA is not brought by an industry insider, which may reduce the focus on the drug pricing elements of the new Medicare program and highlight the free enterprise principles at stake, potentially putting the case on a more popular footing.